PETRA, NCT01805908: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) |
|
|
| Terminated | 1 | 3 | Canada | 111In-Pertuzumab + SPECT-CT | Ontario Clinical Oncology Group (OCOG) | Breast Cancer | 06/16 | 06/16 | | |
NCT01918254: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein |
|
|
| Completed | 1 | 66 | Europe | Paclitaxel, Pertuzumab, Perjeta, Lumretuzumab, RO5479599; RG7116 | Hoffmann-La Roche | Breast Cancer | 10/16 | 10/16 | | |
NCT02060253: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer |
|
|
| Completed | 1 | 9 | US | ganetespib, Hsp90 inhibitor STA-9090, STA-9090, paclitaxel, Anzatax, Asotax, TAX, Taxol, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, pertuzumab, Perjeta | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Synta Pharmaceuticals Corp., New York University Cancer Institute | HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer | 06/18 | 06/18 | | |
